Why it matters: Xaira is the landing spot for CEO Marc Tessier-Lavigne, the former Genentech chief scientific officer and Denali Therapeutics co-founder who last year resigned as Stanford ...

A prominent genetics professor at Stanford University in the US ... claimed he misled them whist persuading them to invest $20 million in the biotech, set up to develop a candidate therapy for ...

Stanford University genetics professor Dr. Stanley Cohen paid $29.2 million to settle a lawsuit over misleading claims he made about Nuredis Inc., his now-dissolved biotechnology company.

Strong financial positions reduce risk in biotech investing, prioritizing firms with both current and pipeline drugs. Vertex shows diversified drug development in chronic diseases, underscoring ...

Biotech and biopharma ... Inc., which received a $1 billion investment on March 23, 2024. Led by CEO and chair Marc Tessier-Lavigne, the former Stanford University president, the drug discovery ...

The Stanford Biotechnology Business & Finance Group ... in exploring careers in biotechnology business, management, and investment. This member driven group will host invited speakers from local ...

Brendan, a Pennsylvanian by birth: -Completed a Ph.D. at Stanford ... major investment (into the 8 figures). -Remains an avid investor, focused on market trends and especially biotechnology ...